FUTURE IWG SYMPOSIA

News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf

Immunonephrology CME session entitled “CME 01 - Immune-mediated renal diseases: old drugs and new disease entities” to be held at the 55th ERA-EDTA Congress, in Copenhagen (Denmark).
Click here to access the programme planner and look for CME 01 scheduled on May 24, 2018 at 08:45 - 12:00.
The CME course will focus on two main topics:  “Cyclophosphamide in glomerular disease: is this old drug still to be used or does it have to be dismissed?” and “Renal involvement in rare inflammatory diseases.”

Meet the ERA-EDTA – the IWG Chair and Vice Chair will be happy to meet IWG ordinary members and colleagues at ERA-EDTA Booth (n. 2.291) of the Congress Exhibition area of Bella Center Copenhagen.
Vladimir Tesar (Chair)
Friday, May 25 at 10.00-11.00
Marten Segelmark (Vice Chair)
Saturday, May 26 at 10.00-11.00


CME Course 'How to become your local expert in Nephrogenetics'
October 8-9, 2018
Belgrade (Serbia)
Click here for more information